Diabetic Macular Edema

Confronting issues unique to aging may lead to better outcomes.

A team of investigators from the University of Michigan may have unlocked a potential new recipe for counteracting the impact that COVID-19 has on patients with underlying disease processes such as type 2 diabetes.

XIPERE, the first therapy utilizing the suprachoroidal space, demonstrates rapid efficacy, durable benefit, and favorable safety profile.

MicroPulse can reduce burden of injections for patients with diffuse diabetic macular edema.

Researchers set out to identify clinical and anatomic factor-associated vision loss in eyes with treatment-naïve DME and good initial VA.

John Pollack, MD, discusses gene therapy advancements in the first installment of his blog for Modern Retina.

A study in the United Arab Emirates reported a possible link between adverse ocular events and a COVID-19 vaccination.

Investigators find that wearable aid offers improved mobility.

Javier Zarranz-Ventura MD, PhD, FEBO, discusses the key highlights from his presentation on a clinical investigation of suitable naïve versus pre-treated DME patients, and what it means for future research.

Dr. Jorge Calzada's diabetic macular edema blog dives into his successful treatment of DME with MicroPulse.

Ophthalmologists face challenges of drug delivery for retinal diseases.

Key takeaways from a discussion on the management of age-related macular degeneration, diabetic macular edema, and inherited retinal disease and insight regarding what to look forward to as the field advances.

The impact of the COVID-19 pandemic on the management of patients with retinal disorders and considerations for how new practices may be adopted into future practice.

Dr Mariya Moosajee comments on the next generation of gene therapy for inherited retinal disease and highlights various systems under investigation.

Visual benefit is not seen during first 2 years of Protocol W study.

Considerations for treating retinal disorders with sustained-release drug delivery implants in an effort to address current treatment challenges in the field.

Dexamethasone implant, aflibercept offer a safe treatment option for diabetic macular edema.

In response to a previously published article, three ophthalmologists present their views on intravitreal pharmacotherapy injections.

An overview of delivery systems under investigation for retinal disorders and implications for future use.

Despite setbacks in DME, Adverum Biotechnologies said it will continue to develop ADVM-022 for wet AMD.

A discussion highlighting new agents under investigation for retinal disorders and implications for future use based on data revealed in more recent clinical trials.

Ophthalmologists highlight recent treatment advances in diabetic macular edema and wet age-related macular degeneration.

If approved, Genentech’s treatment of faricimab will be the first and only medicine targeting two distinct pathways, Ang-2 and VEGF-A, that often cause retinal diseases that may cause vision loss.

Types of delivery methods currently being explored to improve treatment for patients with retinal disorders.

Following a discussion regarding drug delivery challenges in retinal disease, a panel of global experts suggest what types of technological requirements and improvements they would like to see occur in the field.